Freedman DS, Williamson F., Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. Am J Epidemiol. 1995; 141:637-644

Frolich ED, Uric acid: a risk factor for coronary heart disease JAMA. 1993; 270: 354-359.

Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G., Lakka HM, Lakka TA, Solonen JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men. Arch Int Med 2004; 164: 1546-1551.

Staessen J. The determinants and prognostic significance of serum uric acid in elderly patients of the European working party on high blood pressure in the elderly trial. Am J Med 1991; 90 (Suppl 3A): 3A-54S.

Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron.1991; 59: 364-368.

Verdecchia P, Schillaci G., Reboldi GP Santeusanio F, Porcellatic, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. Hypertension 2000; 36: 1072-1078.

Johnson RJ, Kang DH, Feig D., Kivlinghn S., Kanellis J., Watanabe S., Tuttle KR, Rodríguez-Iturbe B, Herrera-Acosta J., Mazzali M. Is there a pathogenetic role of uric acid in hypertension and cardiovascular and renal disease?. Hypertension. 2003; 41: 1183-1190.

Hayden MR and Tyag: SC Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metabol. 2004; 10: 1-15.

Gertler MM, Driskell MM, Bland EF, Garn SM, Learman J., Levine SA, Sprague HB, white PD. Clinical aspects of coronary heart disease; an analysis of 100 cases in patients 23 to 40 years of age with myocardial infarction. J Am Med Assoc 1951; 146: 129-1295.

Hayden MR. Global risk reduction of reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy. Med Hypot Res 2004 1:171-185.

Kannel WB, Castelli WP, Mc Namara PM. The coronary profile 12 years follow-up in the Framingham study. J Occup Med 1967; 9: 611-619.

Weiss R., Dziura J., Burget TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, López M., Saroye M., Morrison J., Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N. Engl J. Med. 2004; 350: 2362-2374.

Zaranoni I, Mazza S, Fantucci M., Dall Aglio E., Bonora E., Delsignore R., Passeri M., Reaven GM. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricemia. J Intern Med 1993; 23:25-30

Rosa F., Vásquez J., Antequera R., Romero-Vecchione E. Hiperreactividad cardiovascular a la estimulación de la región anteroventral del tercer ventrículo de ratas con síndrome metabólico experimental. Rev Soc Esp Cardiol. 2005; 58 (Suppl. 1) : 70.

Romero Vecchione E., Vásquez J., Antequera R., Rosa F., Hiperreactividad del miocardio al isiproterenol en ratas con síndrome metabólico experimental. Rev Soc Esp Cardiol. 2005; 58 (Suppl. 1): 81.

Farquahrson CA, Butler R., Hill A., Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221-226.

Alderman MH, Cohen H., Madharan S., Kivlighn S., Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999; 34: 144-150.

Langlois M., De Bécquer D., Duprez D., Debuyzere M., Delanghe J., Blaton V., Serum uric acid in hypertensive patients with and without peripheral arterial disease. Atherosclerosis. 2003; 168: 163-168.

Butler R., Morris AD, Belch JJ, Hill A., Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension; 2000; 35:746-751.

Mazzali M., Hughes J., Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan Hy, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension; 2001;38:1101-1106.

Ogura T, Matsuura K., Matsumoto Y., Mimura Yl, Kishida M., Otsuka F., Tobe K.. Recent trends of hyperuricemia and obesity in japanese mal adolescents, 1991-2002. Metabolism. 2004; 53:448-453.

Bedir A., Topbas M.,Tanyeri F., Alvur M., Arik N. Leptin might be a regulator of serum uric acid concentration in humans. Jpn Heart J. 2003; 44: 527-236.

Santos CX, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrate multiple reactions, free radical formation and amplification of lipid oxidation. Arch Biochem Biophys. 1999;372: 285-294.

Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett. 1999; 446: 305-308

Naghari M., John R., Naguib S., Sladaty MS, Grasu R., Kurian KC, Van Winckle WB, Soller B., Litovsky S., Madjid M., Willerson JT, Casseells W. PH heterogenicity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis 2002; 164: 27-35.

Sanguinetti SM, Batthyany C., Trostchansky A., Botti H., López GI, Wikinsky RL, Rubbo H., Schreier LE. Nitric oxide inhibits prooxidant actions of uric acid during copper mediated LDL oxidation. Arch. Biochem Biophys 2004; 423: 302-308.

Hayden MR, Tyag SC. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus and atheroscleropathy: a malignant transformation. Cardiovasc Diabetes 2004; 3:1

Vickers s, Schiller HJ, Hildreth JE, Bulkley GB. Immunoaffinity localization of the enzyme xantinooxidase on the outside surface of the endothelial cell plasma membrane. Surgery. 1998; 124:

HSU SP; Pai MF, Peng YF, Chiang CK, HoTI, Hung KY. Serum uric acid levels show a J-shaped association with all cause mortality in hemodialisis patients. Nephrol Dial Transplant. 2004; 19: 457-462.